Treat Adult Plaque Psoriasis | VTAMA® (tapinarof) cream, 1%

#1 Prescribed

Prescribed branded topical treatment for adults with plaque psoriasis*

Join the thousands of prescribers who
have already chosen VTAMA cream.

NUMBERS DON'T LIE. VTAMA cream is the #1 prescribed
branded topical treatment for adults with plaque psoriasis*

200,000+

prescriptions since launch^†

11,000+

unique prescribers^†

2,500+

U.S. pharmacies where MyVTAMA^TM
savings card has been redeemed¹

*IQVIA National Prescription Audit (NPA) for the 3-month period ending 7/28/2023, reflecting estimates of real-world activity. All rights reserved.
^†IQVIA National Prescription Audit (NPA) for the period 5/20/22 to 7/28/2023, reflecting estimates of real-world activity. All rights reserved.

Safety & Tolerability

Patient Experience

NUMBERS DON'T LIE. VTAMA cream is the #1 prescribed branded topical treatment for plaque psoriasis in adults*

200,000+

prescriptions since launch^†

11,000+

unique prescribers^†

2,500+

U.S. pharmacies where MyVTAMA^TM savings card has been redeemed¹

*IQVIA National Prescription Audit (NPA) for the 3-month period ending 7/28/2023, reflecting estimates of real-world activity. All rights reserved.
^†IQVIA National Prescription Audit (NPA) for the period 5/20/22 to 7/28/2023, reflecting estimates of real-world activity. All rights reserved.

Why VTAMA cream?

VTAMA cream is a once-daily, steroid-free treatment for plaque psoriasis in adults²

VTAMA (tapinarof) cream tube

6x the Efficacy vs Vehicle

In two 12-week pivotal studies, the Physician Global Assessment (PGA) success^‡ rate was 36% and 40% for patients using VTAMA cream vs 6% and 6% for patients on vehicle.²
~4 Month Off-Treatment Effect

In an open-label, long-term extension study, the median time to PGA≥2 was 114 days (n=73).^2,3
Favorable Safety and Tolerability

In clinical studies, VTAMA cream showed a favorable and consistent safety profile and was well tolerated, even on sensitive areas of skin.^3-5
^‡PGA success: PGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.

VTAMA (tapinarof) cream tube

References: 1. Dermavant DOF May 2023. 2. VTAMA (tapinarof) cream, 1%. Prescribing Information. Dermavant; 2022. 3. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800-806. 4. Stein Gold L, Kircik L, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: favorable local tolerability in two pivotal phase 3 trials. Poster presented at: Innovations in Dermatology Conference; March 16—20, 2021; virtual. 5. Lebwohl M, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. 6. Dermavant DOF. CSR-DMVT-505-3001. A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults. 2020. 7. Dermavant DOF. CSR-DMVT-505-3002. A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults. 2020. 8. Stein Gold L, Blauvelt A, Armstrong A, et al. Tapinarof cream 1% once daily for plaque psoriasis: secondary efficacy outcomes from two pivotal phase 3 trials. Poster presented at: International Federation of Psoriasis Associations; June 30—July 3, 2021; virtual. 9. Dermavant DOF. PSOARING Patient Images. 2022. 10. Bissonnette R, Strober B, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: patient-reported outcomes from two pivotal phase 3 trials. Poster presented at: American Academy of Dermatology; March 19—23, 2021; San Francisco, CA. 11. Dermavant DOF. CSP-DMVT-505-3001. A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults. 2019. 12. Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor—modulating agent. J Am Acad Dermatol. 2021;84(4):1059-1067. 13. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137:2110-2119. 14. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. 15. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. 16. Kim BE, Howell MD, Guttman E, et al. TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. J Invest Dermatol. 2011;131:1272-1279. 17. Cannavò SP, Riso G, Casciaro M, Di Salvo E, Gangemi S. Oxidative stress involvement in psoriasis: a systematic review. Free Radic Res. 2019;53(8):829-840. 18. Dietrich C. Antioxidant functions of the aryl hydrocarbon receptor. Stem Cell Int. 2016:7943495. 19. Dermavant DOF. The effect of GSK2894512 on the Th2 polarization of human CD4+ T cells and on IL-8 release from TLR2-stimulated keratinocytes. 2015. 20. Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week multicentre, randomized, placebo-controlled double-blind trial. Br J Derm. 2012;166(4):853-860. 21. Bagel J, Stein Gold L, Del Rosso J, et al. Patient satisfaction with tapinarof cream 1% once daily for plaque psoriasis in a long-term extension trial. Poster presented at: Winter Clinical Dermatology Conference; January 14—19, 2022; Kauai, HI. 22. Dermavant DOF. GSK2894512A: Formulation Development Report. 2018.

Back to top